Insulin-like Growth Factor I and Prostate Cancer
Author Information
Author(s): CS Mantzoros, A Tzonou, LB Signorello, M Stampfer, D Trichopoulos, H-O Adami
Primary Institution: Harvard School of Public Health
Hypothesis
Does insulin-like growth factor I (IGF-1) increase the risk of prostate cancer and benign prostatic hyperplasia (BPH)?
Conclusion
The study suggests that IGF-1 may increase the risk of prostate cancer but does not play a role in the aetiology of BPH.
Supporting Evidence
- Increased IGF-1 levels were associated with a higher risk of prostate cancer.
- No significant relation was found between IGF-1 and BPH.
- The study adjusted for demographic and anthropometric factors.
Takeaway
This study looked at blood samples from men with prostate cancer, BPH, and healthy men to see if a hormone called IGF-1 is linked to prostate cancer. They found that higher levels of IGF-1 might mean a higher risk of prostate cancer.
Methodology
Blood samples were collected from 52 prostate cancer cases, 52 BPH cases, and 52 healthy controls, matched for age and town of residence, and analyzed for hormone levels using radioimmunoassay.
Potential Biases
Potential bias due to unreported use of 5 alpha-reductase inhibitors among some patients.
Limitations
The study is relatively small, and case-control investigations cannot establish causality.
Participant Demographics
Participants included 52 men with prostate cancer, 52 with BPH, and 52 healthy controls, matched for age and town of residence.
Statistical Information
P-Value
0.05
Confidence Interval
1.00-3.73
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website